A retrospective study on sperm banking: a Uruguayan experience

Rosina Ordoqui1, Natalibeth Barrera1, José María Montes1, Mariel Canepa1, Carla Bonelli1, Carolina Surka1, Andrea Torrens1, Lidia Cantú1, Stefan S du Plessis2

1Fertilab Laboratorio de Análisis Clínicos, Laboratorio de Andrología, Montevideo, Uruguay
2Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa

This study was presented as a poster in the 13th General Meeting of the Latin American Network of Assisted Reproduction in Buenos Aires, on April 26-28, 2017

ABSTRACT

Objective: The purpose of this study was to investigate the status of homologous sperm banking in Uruguay.

Methods: A retrospective investigation was performed on data collected between 2013 and 2015. Reasons for sperm banking, patient age, pre-freeze and post-thaw semen parameters, and recovery rates were analyzed.

Results: 623 samples were cryobanked between 2013 and 2015. Only 324 samples were considered for analysis after selection based on inclusion criteria. In most cases the samples were stored because the patients were undergoing assisted reproductive technology (ART) treatment (n=190; 58.64%) or for oncological reasons (n=113; 34.88%). The median age of bankers was 34 years. In the cancer group, 61.95% (n=70) of the subjects had been diagnosed with testicular cancer. Medians of semen parameters for both groups were the lower reference limits dictated by the World Health Organization (2010). In fresh samples, a significant difference was observed in progressive motility (47% vs. 56%) between ART and oncological patients. After thawing, total motility (27% vs. 32%), progressive motility (19% vs. 22%), and vitality (48% vs. 56%) differed significantly between ART and oncological bankers.

Conclusion: Semen banking has been performed successfully in Uruguay and outcomes are on par with international standards. Surprisingly, the semen parameters of the cancer group were nearly normal.

Keywords: Sperm, banking, cryopreservation, fertility preservation

INTRODUCTION

Sperm cryopreservation is a biotechnology widely used in andrology laboratories, particularly those associated with assisted reproduction centers (World Health Organization, 2010). The cryopreservation process involves several steps, beginning with exposure of the tissue or cells to cryoprotectants, followed by subsequent cooling to temperatures below zero and long term storing in liquid nitrogen (LN2) at -196°C in order to preserve viability. Finally, a thawing step is employed and physiological conditions are restored. During this complex procedure cells must maintain their integrity (Agca, 2000). The effectiveness of these techniques depends on the cell type, differing among species and individuals. Therefore, it is vital to comprehend the physiology of the material to be cryopreserved in order to ensure their post-thaw survival and functionality (Woods et al., 2004).

Spermatozoa are small cells (22.2±1.2µm³) (Curry et al., 1996) with extremely condensed nuclei, little cytoplasm, and a very high surface to volume ratio. These characteristics give them the peculiarity of being relatively easy to cryopreserve (Saragusty et al., 2011). However, during cryopreservation cells might be damaged for different reasons, including the formation of intracellular crystals, osmotic changes, and mechanical effects associated with the procedure (Centola et al., 1992). Despite some variations in results, most authors agree that sperm fertilization capacity might be affected during cryopreservation (Hammond et al., 1986; Leeton & Backwell, 1976). Reductions in motility, normal morphology, and sperm viability, as well as structural changes in the acrosome, chromatin defects and reduced mitochondrial activity, have been reported and described by several groups (O’Connell et al., 2002; Ozkavukcu et al., 2008). The reasons for cryobanking are numerous. The advent of intracytoplasmic sperm injection (ICSI) in high complexity laboratories has significantly increased the dissemination of cryopreservation, particularly in the preservation of testicular and epididymal spermatozoa. Moreover, sperm cryopreservation has also been indicated for patients undergoing vasectomy, vasovasostomy, and recommended for individuals undergoing cancer treatment (Anger et al., 2003).

Sperm freezing techniques have been used in andrology laboratories for many years (Liu et al., 2016). Fertilab, the only sperm bank in Uruguay, has amassed more than 28 years of experience with this technology to help preserve male reproductive capacity. Since opening its doors in 1987, Fertilab has banked more than 1528 homologous semen samples. The number of cases has increased through the years, and exponential growth has been recently observed, as 139 samples were banked in 2015 versus 77 in 2012 (81% increase in four years). To our knowledge, there currently is very little data available on the Uruguayan experience with sperm banking. This retrospective study aimed to illustrate the status of homologous sperm cryopreservation in the only sperm bank in Uruguay. Furthermore, the results obtained from our laboratory were discussed in great detail by comparing them to data from various similar studies published in the literature. Finally, our results were used to determine possible shortcomings of our sperm banking system, find solutions to improve the technical aspects of cryopreservation, and offer recommendations to promote a wider adoption of the technology in Uruguay.

MATERIALS AND METHODS

Study Population

Our institutional review board approved the study. A total of 623 samples were cryobanked between 2013 and 2015 at Fertilab, including ejaculated semen samples and samples taken from testicular biopsies. The study included only the first ejaculated semen sample banked for each individual patient, on which cryotolerance tests were performed. The included samples were collected prior to the onset of gonadal toxicity and the start of radiation therapy.
Samples from patients under 18 years of age were excluded from the study. In the end, 324 samples met the inclusion criteria.

Reasons for sperm banking, patient age, pre-freeze and post-thaw semen parameters, and recovery rates were reviewed. Semen samples were manually analyzed, according to the guidelines prescribed by the laboratory manual on semen analysis published by the World Health Organization (WHO) (World Health Organization, 2010). Concentration, total sperm motility, progressive motility, and vitality (by eosin-nigrosin staining) were recorded before cryopreservation.

**Semen cryopreservation**

Ejaculates were cryopreserved according to the standard protocol followed at Fertilab. Semen samples were quickly divided into two equal parts and washed in Earle’s balanced salt solution (EBSS) without HEPES by centrifugation (300xg, 5 min). The supernatant was removed and EBSS was added to the pellets in a single tube (final volume 0.5mL). Freezing medium (TYB, Irvine Scientific) was added to a final ratio of 1:1. The samples were incubated for 20 min at room temperature (RT) and were then loaded into 0.25mL straws. Subsequently the straws were placed in nitrogen vapor for 20 min before being dipped in LN2 and stored at -196°C. After 1 min, a straw from each sample was thawed for cryotolerance testing. The frozen aliquots were thawed according to the laboratory’s standard protocol. The samples were kept for 3 min in a pre-warmed conical tube at 40°C. Thereafter the content of the straw was expelled into a different conical tube for immediate routine sperm analysis. Post-thaw sperm motility and vitality were assessed. Recovery rates for motility (i.e., proportion of pre-freeze sperm that remained with progressive motility immediately after thawing) and recovery rates for viability (i.e., proportion of pre-freeze sperm that remained vital and immobile immediately after thawing) were subsequently determined.

**Statistical Analysis**

Statistical analysis was performed on software package XLSTAT (Addinsoft, USA). Data normality was assessed through the Shapiro-Wilk test. Since the variables did not follow a normal distribution, the differences between pre-freeze and post-thaw semen parameters were assessed through the Friedman test. Comparisons between groups were made using a non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Data were expressed in the form median values and interquartile ranges. Differences with p-values <0.05 were considered statistically significant. Qualitative data were expressed as proportions and total number of samples under a specific category.

**RESULTS**

**Reasons for sperm banking**

This retrospective study examined 324 ejaculated samples banked from 2013 to 2015. In most cases the samples were stored because the patients were undergoing assisted reproductive technology (ART) treatment (n=190; 58.64%) or for oncological reasons (n=113; 34.88%). The median age of bankers was 34 years (28-40); as expected, the subpopulation of pre-vasectomy bankers was older and had a median of 44 years (40-45). Bankers in the cancer group were significantly younger than all other bank groups (including ART and pre-vasectomy individuals), with a median age of 28 years (22-33); approximately 75% of the male cancer patients were aged 33 or younger.

In the cancer group, 61.95% (n=70) of the subjects had been diagnosed with testicular cancer, followed by lymphoma (Hodgkin’s and non-Hodgkin’s lymphomas) (12.39%; n=14), leukemia (3.54%; n=4), thyroid tumors (3.54%; n=4), bone marrow aplasia (2.65%; n=3), prostatic tumors (2.65%; n=3), lung tumors (0.88%; n=1), and melanoma (0.88%; n=1). Surprisingly, 3.54% (n=4) of the bankers did not know the type of cancer they had, while another 7.96% (n=9) banked sperm before initiating chemo or radiation therapy without providing information on cancer type. The 190 samples in the ART group were banked as precautionary backup. In this group, 3.16% (n=6) of the men banked sperm because of their possible absence during the time of treatment (regular trips; living in different towns), while the rest of the cohort stored because sperm parameters are known to oscillate or due to potential difficulties having semen samples collected on treatment day.

Table 1 summarizes the seminal parameters of the ART, oncological and total groups before freezing. Significant difference was found only in progressive motility between the ART and cancer groups. No differences were found in concentration, although 25% of the ART bankers had sperm concentrations below 2.5x10^6/mL and 25% of the cancer patients had concentrations below 7x10^6/mL. Interestingly, the two groups had semen parameters above the lower reference limits published in the 2010 WHO guidelines (WHO, 2010). Cryptozoospermic specimens (ART n=7; Oncological n=4) were not considered in the calculation of median values.

**Semen Parameters before and after cryopreservation**

The proportions of spermatooza showing total and progressive motility, the proportions of live spermatooza (vitality) before and after cryopreservation, and recovery rates are shown in Table 1. Only pre-freeze progressive motility differed significantly between the ART (47%) and cancer (56%) groups. Post-thaw total and progressive motility and vitality were significantly different between the ART and cancer groups (p<0.05), with specimens from the cancer group consistently displaying higher values. As expected, a significant reduction occurred in all three pre-freeze semen parameters compared to their respective post-thaw values (p<0.05). The calculated recovery rates for progressive motility and vitality did not differ between the three groups. Interestingly, the cancer group had slightly better recovery rates than the ART group. The samples were subsequently stratified into four groups based on motility and concentration profiles (Normozoospermia, Oligozoospermia, Asthenozoospermia, and Oligoasthenozoospermia) according to the WHO 2010 reference values. The recovery rates based on progressive motility and viability were calculated and compared between groups (Table 2). The recovery rates for progressive motility and vitality were significantly higher for normozoospermic samples versus any of the other three groups. No differences in recovery rates were found between samples having one (oligo- or asthenozoospermia) or two (oligoasthenozoospermia) affected semen parameters before freezing.

Oligozoospermic specimens were further sorted into groups based on severity (mild: 10-15x10^6/mL, moderate: 5-10x10^6/mL; and severe: less than 5x10^6/mL) and their sperm parameters before and after cryopreservation were compared and recovery rates calculated accordingly (Table 3). Samples categorized as severely oligozoospermic showed significantly less progressive motility and vitality before freezing and after thawing. Interestingly, the cryosurvival recovery rates of this group were also significantly lower than the rates seen in the groups with mild and moderate oligozoospermia (p<0.05).
**Table 1.** Pre-freeze and Post-thaw semen parameters of ART, Oncological and Total Group.

| Parameter          | ART Treatment n=183 | Oncological n=109 | Total n=313 |
|--------------------|---------------------|------------------|-------------|
| **Pre freeze**     |                     |                  |             |
| Semen Volume (ml)  | 3 (2-4)             | 2.5 (2-3.9)      | 2.5 (2-4)   |
| Count (x 10^6/ml)  | 20 (2.55-48.0)      | 18 (7-45)        | 20 (4-50)   |
| Total Motility (%) | 59 (42.50-71)       | 64 (50-72)       | 62 (47-72)  |
| Progressive Motility (%) | 47 (28.50-61.50)* | 56 (41-64)       | 53 (34-64)  |
| Vitality (%)       | 90 (82-94.50)       | 92 (87-95)       | 91 (83-95)  |
| **Post-thaw**      |                     |                  |             |
| Total Motility (%) | 27 (17-36)*         | 32 (21-42)       | 28 (17-38)  |
| Progressive Motility (%) | 19 (9-29)*         | 22 (14-35)       | 21 (10-31)  |
| Vitality (%)       | 48 (30.5-61)*       | 56 (39-67)       | 49 (32-64)  |
| **Recovery rate (%)** |                   |                  |             |
| Progressive Motility | 41.3 (24.3-58)     | 47.4 (31.9-58.6) | 44.4 (25-58.6) |
| Vitality           | 56.1 (39-68.9)      | 61.1 (46.2-73.2) | 57.3 (40.8-70.8) |

* p<0.05 vs. cancer patients by Dunn's multiple comparisons test.

**Table 2.** Recovery rates for progressive motility and vitality according to semen quality.

| Parameter                  | Normozoospermia (n=149) | Oligozoospermia (n=153) | Asthenozoospermia (n=77) | Oligoasthenozoospermia (n=55) |
|----------------------------|--------------------------|-------------------------|--------------------------|-------------------------------|
| Recovery rate (%)          |                          |                         |                          |                               |
| Progressive Motility       | 49.18 (34.62-60)         | 33.3 (16.18-54.05)*     | 36.67 (12.50-60)*        | 21.43 (0-57.5)*               |
| Vitality                   | 62.5 (47.42-75.26)       | 48.45 (31.91-67.37)*    | 47.76 (24.14-62.37)*     | 40.74 (20.32-58.57)*          |

* p<0.05 vs. Normozoospermia

**Table 3.** Pre-freeze and post-thaw semen parameters of mild, moderate, and severe oligozoospermia samples.

| Parameter                  | Mild (10 - 15 x 10^6/ml) n=22 | Moderate (5 - 10 x 10^6/ml) n=39 | Severe (< 5 x 10^6/ml) n=92 |
|----------------------------|--------------------------------|----------------------------------|----------------------------|
| Pre-freeze                 |                                |                                  |                            |
| Progressive Motility (%)   | 55 (41- 65.75)*                | 47 (33.5- 57.5)*                 | 33 (17- 44)                |
| Vitality (%)               | 94 (87.25- 95)*                | 92 (87- 95)*                     | 86 (68.5- 93)              |
| Post-thaw                  |                                |                                  |                            |
| Progressive Motility (%)   | 26 (19.25- 31)*                | 20 (13- 28.5)*                   | 15 (9- 10.17)              |
| Vitality (%)               | 49 (33.75- 64)*                | 48 (40 -62)*                     | 32 (17.5 -49.5)            |
| Recovery rate (%)          |                                |                                  |                            |
| Progressive Motility       | 44.4 (37.45- 54.84)*           | 42.31 (29.35- 64.41)*           | 22 (10.5- 48.6)            |
| Vitality                   | 53.31 (42.33- 68.29)*          | 55.91 (47.41- 68.13)*           | 41.26 (27.27- 64.46)       |

*p<0.05 vs. severe by Dunn's multiple comparisons test.

**DISCUSSION**

Over the last few decades, improvements in medical reproductive technology contributed significantly to increase the number of sperm bankers, particularly since the introduction of ICSI. Fertilab established the first human sperm bank in Uruguay in 1987 (Fertilab, 2016). To date, 1397 patients have had sperm samples stored with Fertilab. Although the technique is well established globally and locally, and despite the increase in utilization observed over the last few years in Uruguay, the general population and even some medical professionals are still not familiarized with the technique and its applications. A clear example of the magnitude of this problem is that only 6.4% of the 2038 male individuals aged between 15 and 40 years diagnosed with cancer in the 2007-2011 period registered with the National Cancer Institute of Uruguay (Barrios et al., 2014) used cryopreservation to help preserve their fertility. Therefore, finding out more about the Uruguayan cryobank population might help identify gaps and pinpoint specific areas (ART centers, oncological professionals, and urological professionals) where information on sperm cryopreservation is lacking, so as to help highlight the potential benefits of cryobanking.
In our laboratory, the primary group resorting to sperm cryopreservation comprises infertile couples looking to store sperm prior to ART (58.64%). Previous studies have reported similar findings for fresh or frozen sperm used in ICSI cycles (Cayan et al., 2001; Kalsi et al., 2011). Sperm banking for this reason is usually limited to a few months to help reduce male anxiety and ensure there is a backup sperm sample available on the day of ART. Some couples undergo ART treatment when the man is not physically present during egg retrieval or at the time the woman is fertile, and in such cases semen cryopreservation might be the only solution (Ping et al., 2010).

Cancer patients were the second largest group (34.87%) to seek semen cryopreservation. The survival rates of most cancer types continue to improve with the advancement of treatment options in recent decades (Pacey & Eiser, 2011). Consequently, the number of men of reproductive age suffering from malignant diseases has grown. The preservation of fertility before and after treatment is very important for many of them (Williams, 2010). According to our results, the median age of the subjects storing semen samples prior to cancer treatment is 28 years (33-42), making them significantly younger than the individuals in the ART group (median age of 34 years, ranging between 28-40 years). Similar results have been reported in the literature (Hotaling et al., 2016; Tomlinson et al., 2015). This clearly demonstrates the desire these patients have to preserve their chances of becoming parents, and the notion that sperm cryopreservation is the only option they have to fulfill their aspirations of parenthood.

The most frequent types of cancer reported in our laboratory were testicular tumor (61.95%) and lymphoma (12.39%). Our results are in agreement with previous findings reported in the study by Depalo et al. (2016), in which patients with testicular cancer (seminoma) and Hodgkin’s Lymphoma topped the list of oncological cryobank users. A possible explanation for this phenomenon is that the prognosis for these cancer types is better, and therefore patients are more likely to be encouraged by their treating physicians to opt for fertility preservation. The National Cancer Institute in Uruguay reported that 412 patients between the ages of 15 and 44 years were diagnosed with testicular cancer from 2007 to 2011. During the same period, 82 patients with this condition had sperm specimens cryopreserved at Fertilab, thereby accounting for 20% of the population diagnosed with testicular cancer in the nation. Surprisingly, the proportion of patients with other cancer types banking at Fertilab was lower: 12 of 79 (15.2%) individuals diagnosed with Hodgkin’s Lymphoma; 10 of 190 (5.3%) subjects diagnosed with Non-Hodgkin’s Lymphoma; and four of 117 (3.4%) patients diagnosed with colon cancer. From this picture, it appears that clinicians and patients see testicular cancer as having a stronger correlation with infertility than any of the other cancer types, since a higher proportion of individuals with this disease have sought cryopreservation services. The literature shows an evident association between testicular cancer and impaired fertility in the form of lower sperm concentration levels and fewer live births (Baker et al., 2005). However, this perception tends to overlook a population of young men suffering from a variety of malignant diseases and leave them vulnerable, as cancer treatment engenders a roster of complex impacts on fertility. And health professionals often underestimate these impacts.

The third largest category of cancer-related reasons for sperm banking included patients looking to cryopreserve sperm before the start of cancer treatment (chemotherapy or radiation therapy). The exact types of cancer these patients were diagnosed with are unknown, thus illustrating the inexistence of proper communication between oncologists and infertility physicians. It is well known that cancer treatment is frequently aggressive and might produce several side effects, including significant threats to male fertility potential. It is impossible to predict the impact of cancer treatment on fertility, as it might cause transient or permanent infertility (chemotherapy: factors include patient age, drug type and dosage; radiation therapy: factors include the site of irradiation, dosage, and type). For these reasons, sperm cryopreservation prior to cancer treatment is highly recommended for patients desiring to have a chance of becoming biological parents in the future (ASRM, 2013). Unfortunately, our data indicated that only a small proportion of cancer patients have sperm specimens cryopreserved. This finding is corroborated by studies carried out in developed nations (UK) (Zapzalka et al., 1999). Three factors appear to be connected to this phenomenon: (i) lack of awareness, since oncologists and patients do not comprehend the adverse impact of cancer treatment on germ cells and fertility, which leads oncologists not to refer patients and patients not to seek sperm cryopreservation; (ii) patients focus exclusively on having treatment for their oncological conditions, thereby ignoring future fertility plans and disregarding sperm cryopreservation prior to the start of treatment; and (iii) the discouraging price tag attached to cryobanking and long term storage (Ping et al., 2010). These patients in particular should use sperm banks. It is crucial that everyone involved understands that banking implies a chance of future parenthood. The mere fact that oncologists discuss fertility preservation with their patients might indicate that the disease might offer a better prognosis. This might impact patient self-esteem and self-preservation, which in turn might work as psychological protection (Pacey & Eiser, 2011).

Compared to other cell types, spermatozoa are less sensitive to cooling processes due to the high fluidity of their membrane and their low water content (<50%). However, despite these characteristics, cryopreservation produces deleterious effects on spermatozoa structure and functionality (Oberoi et al., 2014), causing decreases in motility, viability, chromatin stability, and membrane integrity, thus inducing morphological alterations (Hammad et al., 1999).

Loss of sperm motility is one of the parameters commonly reported in the literature (Sharma et al., 2015), in addition to used cryoprotective medium, freezing technique, specimen quality, and specimen resistance to freezing and thawing. On average, only 50% of motile sperm survive the freeze-thaw process (World Health Organization, 2010). A loss of 20% in total motility is common for donor samples (Matorras & Hernández, 2007), while sample quality decreases dramatically in patients whose initial semen parameters fall outside normal ranges (Hammad et al., 1999). Table 1 summarizes the pre-freeze and post-thaw seminal parameters according to three groups (Total, ART and Oncological). The rate of recovery of progressive motile spermatozoa was close to 45% for the total population, which is lower than what has been reported in the literature (Creemers et al., 2011; Paras et al., 2008). However, when analyzing data using only normal samples according to the 2010 WHO reference values (Table 2), this proportion increases to 49.19% and reaches commonly reported levels. Surprisingly, the semen parameters of the cancer group were nearly normal (Table 1). A variety of studies have reported that cancer adversely affects semen quality (Colpi et al., 2004; Howell & Shalet, 2005). However, results are contradictory and similar sperm quality in men with and without cancer before cryopreservation has been described (Rofeim & Gilbert, 2004). It is well known that the parameters of the semen sample before freezing determine, among other things, the success of cryopreservation. It has been observed that in approximately 50% of the individuals with malignant disease semen sample
quality is affected even before the onset of chemo or radiation therapy.

It is well known that males contribute to 50% of the infertility cases; male factor is involved when one or more semen parameters are abnormal. Oligozoospermia (<15 million/mL) reportedly occurs in 5% to 18% of subfertile men, while the incidence of specimens with asthenozoospermia (<40% total motility) is seen in 35.5% to 51% of the cases. Abnormal semen parameters often manifest in combination with a condition known as oligoasthenozoospermia, which can be found in up to 21.5% of semen samples of individuals seeking infertility treatment (Acacio et al., 2000; Aleisa, 2013). In a study performed in Brazil, a significant reduction in sperm motility was observed after cryopreservation was offered to a group of patients with baseline concentration and motility values below normal levels as established by the WHO in 1999 (Esteves et al., 2003). The post-thaw sperm recovery rate was close to 20% and the vitality index reached approximately 52%; these values were in agreement with the values reported in this study in patients with oligoasthenozoospermia (Table 2). The analysis of our data revealed that there were no significant differences (p>0.05) in the post-freeze vitality and motility indices between samples with one or two altered baseline semen parameters (oligo- or astheno- vs. oligoasthenozoospermia) (Table 2). In addition, no significant differences were observed in the recovery rates of oligo- or asthenozoospermic samples (p>0.05). However, these rates were significantly reduced when compared to normozoospermic samples. One might assume that fresh samples with either subnormal concentration or motility might indicate poorer post-thaw recovery rates regardless of the affected baseline parameter. These results are in agreement with the findings published by Huang et al. (1991), in which significant differences were observed in the survival rate of oligozoospermic vs. normozoospermic samples (39.0% vs. 73.3%). These authors also found that the survival rate of oligoasthenozoospermic specimens was different from normal specimens (35% vs. 73.3%), but not from specimens in which only concentration was affected. It is widely accepted that sperm viability is affected by cryopreservation. As confirmation to this notion, a decrease in viable cells (vitality index = 50%) has been reported in samples from proven fertile and subfertile men (Vieira et al., 2012). Interestingly, outcomes appear to improve when rapid cryopreservation protocols are used in comparison to slow freezing methods (64.8% vs. 50.4%) (Vutyavanich et al., 2010). Our post-thaw viability recovery results (Normozoospermic = 62.5%; Oligozoospermic = 48.45%) were very much in agreement with these and other reports in the literature.

The capacity to cryopreserve oligozoospermic samples has numerous advantages, including storage of samples from patients with severe oligozoospermia (Schuster et al., 2003). The introduction of ICSI has changed the outcome of many couples facing this diagnosis and who previously required donor samples. Findings suggest that it is important to advise men with severe oligozoospermia of the possible decay in sperm parameters, sperm count in particular. This phenomenon might more than likely cause 40% of the oligospermic population to become azoospermic. Therefore, recommendation for sperm cryopreservation when the initial sperm count is lower than 5 million/mL has been suggested (Kolta et al., 2015). However, specimens of this type are challenging to cryopreserve and traditional methods seem to be ineffective (Di Santo et al., 2012). Our results showed significantly lower post-thaw recovery rates for patients with severe oligozoospermia when the concentration was lower than 5x10^6/mL compared to moderate and mild cases (Table 3). Vitrification is a fairly new and alternative cryopreservation method that has been suggested for cryopreserving samples, including the ones retrieved after testicular and epididymal biopsies. Abdelhafez et al. (2009) carried out an exhaustive literature review on several publications related to sperm vitrification (epididymis and testicular samples). The sperm recovery rate varied between 59-100% and publications reporting fertilization data described rates between 18-67%. It has been demonstrated that the use of vitrification does not appear to be advantageous with normozoospermic samples, with values of motility, viability, DNA fragmentation, and post-vitrification morphology remaining similar to values obtained using a fast freezing protocol (Agha-Rahimi et al., 2014). Other strategies need to be developed to optimize the cryopreservation of these valuable samples (epididymal and testicular sperm and for severe oligozoospermia).

Finally, the importance of sperm cryopreservation in andrology laboratories and assisted reproduction centers is indisputable. This technology can be used successfully in high complexity laboratories, inter alia for storage of semen samples from donors, patients with severe male factor infertility, and preservation of fertility in cancer patients. Our retrospective study illustrated the current landscape of sperm cryopreservation in Uruguay, reflecting the lack of discussions between patients and doctors of fertility preservation options before gonadotoxic therapies. It also hinted that counseling must be improved, and that a stronger interdisciplinary network should be built to include oncologists, psychologists, and reproduction specialists. A second important point is to perform more prospective studies to redesign the current cryopreservation protocols for samples with very severe oligozoospermia in order to obtain better recovery rates for this group of patients. Additionally, in order to develop a better understanding about the use of banked samples, future studies must evaluate the successful application of homologous sperm cryopreservation on the reproductive outcome of ART patients in Uruguay. In conclusion, semen banking is performed successfully in Uruguay and in many aspects the outcomes are on par with international standards.

**Conflicts of interest**

The authors have no conflicts of interest to declare.

**Funding sources**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Corresponding Author:**

José María Montes
Fertilab Laboratorio de Análisis Clínicos, Laboratorio de Andrología Montevideo, Uruguay
E-mail: montes@fertilab.com.uy

**REFERENCES**

Abdelhafez F, BedawiY M, El-Nashar SA, Sabanegh E, Desai N. Techniques for cryopreservation of individual or small numbers of human spermatozoa: a systematic review. Hum Reprod Update. 2009;15:153-64. PMID: 19109313 DOI: 10.1093/humupd/dm061

Acacio BD, Gottfried T, Israel R, Sokol RZ. Evaluation of a large cohort of men presenting for a screening semen analysis. Fertil Steril. 2000;73:595-7. PMID: 10689019 DOI: 10.1016/S0015-0282(99)00591-9

DOI: 10.1590/1806-9795-0712

JBRA Assist. Reprod. | v.22 | nº2 | Apr-May-Jun/ 2018
Agha Y. Cryopreservation of oocyte and ovarian tissue. ILAR J. 2000;41:207-20. PMID: 11123181 DOI: 10.1093/ilar.41.4.207

Agha-Rahimi A, Khalili MA, Nabi A, Ashourzadeh S. Vitrification is not superior to rapid freezing of normozoospermic spermatozoa: effects on sperm parameters, DNA fragmentation and hyaluron binding. Reprod Biomed Online. 2014;28:352-8. PMID: 24444814 DOI: 10.1016/j.rbmo.2013.11.015

Aleisa NAS. Semen characteristics of fertile and subfertile men in a fertility clinic and correlation with age. J King Saud Univ Sci. 2013;25:63-71. DOI: 10.1016/j.jksus.2012.06.002

Anger JT, Gilbert BR, Goldstein MA. Cryopreservation of sperm: indications, methods and results. J Urol. 2003;170:1079-84. PMID: 14501696 DOI: 10.1097/01.ju.0000084820.98430.b8

ASRM - Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2013;100:1224-31. PMID: 24094423 DOI: 10.1016/j.fertnstert.2013.08.041

Baker JA, Buck GM, Vena JE, Moysich KB. Fertility patterns prior to testicular cancer diagnosis. Cancer Causes Control. 2005;16:295-9. PMID: 15947881 DOI: 10.1007/s10552-004-4024-2

Barrios E, Garau M, Alonso R, Musetti C. IV Atlas of incidence of cancer in the Uruguay 2007-2011. Montevideo: Comisión Honoraria de Lucha Contra el Cáncer; 2014.

Cayan S, Lee D, Conaghan J, Givens CA, Ryan JP, Schrock ED, Turek PJ. A comparison of ICSI outcomes with fresh and cryopreserved epididymal spermatozoa from the same couples. Hum Reprod. 2001;16:495-9. PMID: 11228218 DOI: 10.1093/humrep/16.3.495

Centola GM, Raubertas RF, Mattox JH. Cryopreservation of human semen: Comparison of Cryopreservative sources, Variables of Variability, and Prediction of Post-thaw Survival. J Androl. 1992;13:283-8. PMID: 1601749 DOI: 10.1002/j.1939-4640.1992.tb00316.x

Colpi GM, Contalbi GF, Nerva F, Sagone P, Piediferro G. Testicular function following chemo-radiotherapy. Eur J Obstet Gynecol Reprod Biol. 2004;113:S2-6. PMID: 15041121 DOI: 10.1016/j.ejnod.2003.11.002

Creemers E, Nijs M, Vanheusden E, Ombelet W. Cryopreservation of human sperm: efficacy and use of a new nitrogen-free controlled rate freezer versus liquid nitrogen vapour freezing. Andrologia. 2011;43:392-7. PMID: 21848872 DOI: 10.1111/j.1439-0272.2010.01070.x

Curry MR, Millar JD, Tamull SM, Watson PF. Surface area and volume measurements for ram and human spermatozoa. Biol Reprod. 1996;55:1325-32. PMID: 8949890 DOI: 10.1095/biolreprod55.6.1325

Depalo R, Falagario D, Masiandaro P, Nardelli C, Vaccia MP, Capuano P, Specchia G, Battaglia M. Fertility preservation in males with cancer: 16-year monocentric experience of sperm banking and post-thaw reproductive outcomes. Ther Adv Med Oncol. 2016;8:412-20. PMID: 27800030 DOI: 10.1177/1758834016665078

Di Santo M, Tarozzi N, Nadalini M, Borini A. Human Sperm Cryopreservation: Update on Techniques, Effect on DNA Integrity, and Implications for ART. Adv Urol. 2012;2012:854837. PMID: 22194740 DOI: 10.1155/2012/854837

Esteses SC, Spaine DM, Cedenho AP, Srougi M. Effects of the technique of cryopreservation and dilution centrifugation after thawing on the motility and vitality of spermatozoa of oligoasthenozoospermic men. Int J Androl. 2003;29:133-9. PMID: 15745946 DOI: 10.1159/107177-5538200300200007

Fertilab. Banco de gametos. [cited 2016 Jul 1]. Available at: http://www.bancodegametos.com.uy/

Hammad ME, Askari AS, Georg T, Rosenbaum P, Schmidt W. Effect of freeze-thawing procedure on chromatin stability, morphological alteration and membrane integrity of human spermatozoa in fertile and subfertile men. Int J Androl. 1999;22:155-62. PMID: 10367235 DOI: 10.1046/j.1365-2605.1999.00162.x

Hammond MG, Jordan S, Sloan CS. Factors affecting pregnancy rates in a donor insemination program using frozen semen. Am J Obstet Gynecol. 1986;155:480-5. PMID: 3752170 DOI: 10.1016/0002-9378(86)90258-9

Hotaling JM, Patel DP, Vendryes C, Lopushnyan NA, Presson AP, Zhang C, Muller CH, Walsh TJ. Predictors of sperm recovery after cryopreservation in testicular cancer. Asian J Androl. 2016;18:35-8. PMID: 25999362 DOI: 10.4103/1008-682X.155535

Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005;34:12-7. PMID: 15784814 DOI: 10.1093/jncimonographs/lgi003

Huang CC, Wu NA, Chao RL, Shih IF, Liao CJ, Lee MS. Study on cryosurvival rate of spermatozoa. J Formos Med Assoc. 1991;90:605-8. PMID: 1681008

Kalsi J, Thum MY, Muneer A, Pryor J, Abdullah H, Minhas S. Analysis of the outcome of intracytoplasmic sperm injection using fresh or frozen sperm. BJU Int. 2011;107:1124-8. PMID: 21156015 DOI: 10.1111/j.1464-410X.2010.09547.x

Kolta S, Listijono DR, Chapman MG. Should ART Patients with Severe Oligozoospermia Undergo Sperm Cryopreservation at Time of Initial Diagnosis? Andrology. 2015;4:134. DOI: 10.4172/2167-0250.1000134

Leeton J, Backwell J. Artificial donor insemination. Aust N Z J Obstet Gynaecol. 1976;16:45-7. PMID: 1067082 DOI: 10.1111/j.1479-828X.1976.tb02655.x

Liu J, Tanrikut C, Wright DL, Lee GY, Toner M, Biggers JD, Toth TL. Cryopreservation of human spermatozoa with minimal non-permeable cryoprotectant. Cryobiology. 2016;73:162-7. PMID: 27498216 DOI: 10.1016/j.cryobiol.2016.08.004

Matorras R, Hernández J. Estudio y tratamiento de la pareja estéril: Recomendaciones de la Sociedad Española de Fertilidad, con la colaboración de la Asociación Española para el Estudio de la Biología de la Reproducción, de la Asociación Española de Andrología y de la Sociedad Española de Contracepción. Madrid: Adalia; 2007.
Oberoi B, Kumar S, Talwar P. Study of human sperm motility post cryopreservation. Med J Armed Forces India. 2014;70:349-53. PMID: 25382909 DOI: 10.1016/j.mjafi.2014.09.006

O’Connell M, McClure N, Lewis SE. The effects of cryopreservation on sperm morphology, motility and mitochondrial function. Hum Reprod. 2002;17:704-9. PMID: 11870124 DOI: 10.1093/humrep/17.3.704

Ozkavukcu S, Erdemli E, Isik A, Oztuna D, Karahuseyinoglu S. Effects of cryopreservation on sperm parameters and ultrastructural morphology of human spermatozoa. J Assist Reprod Genet. 2008;25:403-11. PMID: 18704674 DOI: 10.1007/s10815-008-9232-3

Pacey AA, Eiser C. Banking sperm is only the first of many decisions for men: what healthcare professionals and men need to know. Hum Fertil (Camb). 2011;14:208-17. PMID: 22088127 DOI: 10.3109/14647273.2011.634480

Paras L, Freisinger J, Estebauer B, Schmeller N, Szlauer R, Jungwirth A. Cryopreservation technique: comparison of Test yolk buffer versus SpermCryo and vapour versus computerised freezing. Andrologia. 2008;40:18-22. PMID: 18211297 DOI: 10.1111/j.1439-0272.2008.00803.x

Ping P, Zhu WB, Zhang XZ, Yao KS, Xu P, Huang YR, Li Z. Sperm banking for male reproductive preservation: a 6-year retrospective multi-centre study in China. Asian J Androl. 2010;12:356-62. PMID: 20348941 DOI: 10.1038/a.aj.2010.12

Rofeim O, Gilbert BR. Normal semen parameters in cancer patients presenting for cryopreservation before gonadotoxic therapy. Fertil Steril. 2004;82:505-6. PMID: 15302317 DOI: 10.1016/j.fertnstert.2003.12.045

Saragusty J, Hermes R, Göritz F, Hildebrandt TB. Mammalian reproduction out of cryopreserved cells and tissues: current state of the art and future options. Int Zoo Yearb. 2011;45:133-53. DOI: 10.1111/j.1748-1090.2010.00128.x

Schuster TG, Keller LM, Dunn RL, Ohl DA, Smith GD. Ultra-rapid freezing of very low numbers of sperm using cryoloops. Hum Reprod. 2003;18:788-95. PMID: 12660272 DOI: 10.1093/humrep/deg162

Sharma R, Kattoor AJ, Ghulmiyyah J, Agarwal A. Effect of sperm storage and selection techniques on sperm parameters. Biol Reprod Med. 2015;61:1-12. PMID: 25354153 DOI: 10.3109/19396368.2014.976720

Tomlinson M, Meadows J, Kohut T, Haoula Z, Naeem A, Pooley K, Deb S. Review and follow-up of patients using a regional sperm cryopreservation service: ensuring that resources are targeted to those patients most in need. Andrology. 2015;3:709-16. PMID: 26084966 DOI: 10.1111/andr.12045

Vieira MA, Nery SF, Tavares RL, Cruz CD, Reis FM, Camargos AF. Rapid thawing human sperm does not affect basic parameters in normozoospermic men: a double-blind prospective study. Int Braz J Urol. 2012;38:108-15. PMID: 22397772 DOI: 10.1590/S1677-55382012000100015

Vutyavanich T, Piromlertamorn W, Nunta S. Rapid freezing versus slow programmable freezing of human spermatozoa. Fertil Steril. 2010;93:1921-8. PMID: 19243759 DOI: 10.1016/j.fertnstert.2008.04.076

Williams DH. Sperm banking and the cancer patient. Ther Adv Urol. 2010;2:19-34. PMID: 21789080 DOI: 10.1177/1756287210368279

Woods EJ, Benson JD, Agca Y, Critser JK. Fundamental cryobiology of reproductive cells and tissues. Cryobiology. 2004;48:146-56. PMID: 15094091 DOI: 10.1016/j.cryobiol.2004.03.002

World Health Organization (WHO). WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th ed. Geneva: World Health Organization; 2010.

Zapzalka DM, Redmon JB, Pryor JL. A survey of oncologists regarding sperm cryopreservation and assisted reproductive techniques for male cancer patients. Cancer. 1999;86:1812-7. PMID: 10547555 DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1812::aid-cncr24>3.0.co;2-l